LUR

{2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl}acetic acid

LUR is found in 6 entries

LUR as free ligands, exist in 6 entries. Examples include 4IIZ, 4IK6, 4OTY

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

Name {2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl}acetic acid
Identifiers 2-[2-[(2-chloranyl-6-fluoranyl-phenyl)amino]-5-methyl-phenyl]ethanoic acid
Synonyms Lumiracoxib
Formula C15 H13 Cl F N O2
Molecular Weight 293.72 g/mol
Type non-polymer
Isomeric SMILES Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1
InChI InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)
InChI Key KHPKQFYUPIUARC-UHFFFAOYSA-N

Chemical Details

Formal Charge 0
Atom Count 33
Chiral Atom Count 0
Chiral Atoms
Bond Count 34
Aromatic Bond Count 12

Drug Info: DrugBank

DrugBank ID DB01283   (Stereoisomeric match)
Name Lumiracoxib
Groups
  • approved
  • investigational
Description Lumiracoxib is a COX-2 selective inhibitor non-steroidal anti-inflammatory drug. On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling the drug.
Synonyms
  • 2-((2-chloro-6-Fluorophenyl)amino)-5-methylbenzeneacetic acid
  • COX 189
  • COX-189
  • COX189
  • Lumiracoxibum
Brand Names Prexige
Affected Organism Humans and other mammals
Indication For the acute and chronic treatment of the signs and symptoms of osteoarthritis of the knee in adults.
Pharmacology Lumiracoxib has a different structure from the standard COX-2 inhibitors (e.g. celecoxib). It more closely resembles the structure of diclofenac (one chlorine substituted by fluorine, the phenylacetic acid has another methyl group in meta position), making it a member of the arylalkanoic acid family of NSAIDs. It binds to a different site on the COX-2 receptor than the standard COX-2 inhibitors. It displays extremely high COX-2 selectivity.
Mechanism of action The mechanism of action of lumiracoxib is due to inhibition of prostaglandin synthesis via inhibition of cyclooygenase-2 (COX-2). Lumiracoxib does not inhibit COX-1 at therapeutic concentrations.
Categories Cyclooxygenase 2 Inhibitors
ATC-Code M01AH06
AHFS-Code 28:08.04.08
CAS number 220991-20-8
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682